Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
5 days ago

The $600 Million Cut: Ben Affleck’s AI Company, Netflix’s Bet, and the Data Behind the Drama – ( $NFLX $NVDA $SMWB )

Hollywood just added a new kind of tentpole: the AI post‑production startup. Investors would be wise to pay attention, because behind the celebrity headlines around Ben Affleck’s InterPositive sale to Netflix sits an emerging stack that runs straight through NVIDIA (NVDA) and data players like SimilarWeb (SMWB).

When Ben Affleck Becomes A Tech Founder

Ben Affleck did not set out to replace screenwriters with algorithms so much as to rescue overworked crews from continuity errors, bad lighting, and the occasional visible stunt wire. InterPositive, founded in 2022, built filmmaker‑focused AI trained on a production’s own footage to handle reframing, relighting, background cleanup, and other post‑production headaches while preserving the director’s creative fingerprint. The pitch landed spectacularly: Netflix (NFLX) agreed to acquire InterPositive in a deal that securities filings and reporting peg at roughly $587 million in cash, with total consideration that could reach as much $600million via performance‑based earn‑outs. For a company that Hollywood insiders barely knew existed before the announcement, that is less “side hustle” and more “tier‑one exit.”

Netflix Buys, Not Builds

Netflix has historically preferred to build its own technology, yet only days after backing away from a much larger studio acquisition it opted to buy its AI production tools rather than construct them from scratch. The streaming giant is integrating InterPositive’s reported 16‑person team and keeping Affleck on as a senior advisor, effectively in‑sourcing a boutique AI R&D lab for its roughly 300 productions that already lean on AI in some form. The strategic subtext is clear: Netflix wants proprietary, creator‑centric AI that can reduce below‑the‑line costs—Deadline’s read of Affleck’s patent materials suggested double‑digit percentage savings on areas like visual effects, background actors, and art department expenses—while framing the tools as enablers of “more human work,” not fewer human jobs. That is a delicate balancing act, but if it works, Netflix enjoys margin expansion, faster post‑production cycles, and a defensible technological moat around its content machine.

The Invisible Infrastructure: NVIDIA (NVDA)

None of this cinematic alchemy happens in a vacuum; it runs on silicon. Underneath every model that learns the “visual logic” of a film and every GPU‑hungry post‑production pipeline sits hardware from companies like NVIDIA (NVDA). Nvidia’s shares have been on a notable tear—logging a 10‑day winning streak and rising about 18% over that stretch—as hyperscalers and media platforms alike race to secure AI compute. At its recent GTC conference, NVIDIA disclosed orders for graphics processing capacity stretching through 2027, anchored by its Blackwell architecture and upcoming Vera Rubin GPUs, with data center revenue now comprising roughly 88% of the company’s business. For investors, that means each high‑profile AI deployment—whether in streaming, gaming, healthcare, or fintech—functions as another incremental validation of NVDA’s role as the picks‑and‑shovels provider to the AI gold rush. If InterPositive is the director’s assistant, NVIDIA is the studio backlot’s power plant..

Why Data Signals Like SimilarWeb (SMWB) Matter

AI may reshape how films are made, but it does not alter the industry’s oldest law: attention is the scarce asset. That is where analytics platforms such as SimilarWeb (SMWB) enter the picture, offering granular measurements of digital traffic, engagement, and competitive positioning across streaming, social, and broader web ecosystems. For investors, SMWB‑style data provides an early‑warning system for whether Netflix’s bet on proprietary AI actually translates into viewership and subscriber momentum. A sustained lift in site visits, app usage, or time‑on‑platform following the deployment of AI‑enhanced content can be quantified long before GAAP revenue lines fully reflect the impact. In a world where narrative often leads price action, data‑rich observability into that narrative becomes a tradable edge.

The Investor Angle: From Red Carpets To Returns

InterPositive began life with backing from RedBird Capital Partners and ended up as one of Netflix’s largest technology acquisitions, reminding investors that the AI opportunity is not limited to mega‑cap platforms. Specialized vertical tools—here, film‑centric post‑production—can command premium prices when they reduce costs, compress timelines, and integrate cleanly into existing workflows. Public‑market investors watching this drama unfold face a multi‑layered opportunity set: platform buyers such as Netflix (NFLX) seeking margin expansion from production AI, infrastructure leaders like NVIDIA (NVDA) monetizing the compute layer, and data intelligence firms such as SimilarWeb (SMWB) helping quantify which narratives are actually winning in the marketplace. The red carpet may capture the spotlight, but the durable returns tend to accrue to the companies quietly powering, measuring, and scaling the underlying technology.

Ben Affleck – Batman Epic Fight Scene

The Sources

  1. Ben Affleck’s AI Company Is Sold for More Than $500 Million – Yahoo Finance[finance.yahoo]
  2. Ben Affleck Sells His AI Post‑Production Startup InterPositive to Netflix – The Guardian[theguardian]
  3. Ben Affleck Just Sold His ‘Stealth’ AI Startup to Netflix for $600 Million – Inc.[inc]
  4. Netflix Paid $587 Million for Ben Affleck’s AI Startup InterPositive – Variety[variety]
  5. Netflix to Pay as Much as $600 Million for Ben Affleck’s AI Firm – Bloomberg[bloomberg]
  6. Ben Affleck Says the AI Company He Just Sold to Netflix for $600 Million Will Lead to ‘More Human Work’ – Yahoo/Finance/Money[finance.yahoo]
  7. NVDA – NVIDIA Corporation Performance & Analysis – PortfoliosLab[portfolioslab]
  8. NVIDIA (NVDA) Performance Report – Barchart[barchart]
  9. NVIDIA (NVDA) Stock Chart and Price History – MarketBeat[marketbeat]
  10. Similarweb Ltd (SMWB) Company Profile – Investing.com[investing]
  11. Similarweb (SMWB) Stock Price, News & Analysis – MarketBeat[marketbeat]
  12. Similarweb – Company Overview – Wikipedia[en.wikipedia]
  13. Similarweb – About Us[similarweb]

5 days ago

Sable Offshore: Refinancing The Exxon Lifeline Without Spilling The Coffee -( $SOC $XOM )

Sable Offshore Corp. (NYSE: SOC) is one of the market’s most combustible stories: a small-cap oil name with real production upside, serious legal overhangs, and enough headline voltage to keep traders awake and counsel employed. The investment case is not subtle, but it is readable: if the Santa Ynez Unit keeps moving toward stable operations, SOC can look like a turnaround; if the courts and regulators keep tightening the vise, it looks more like a very expensive geology lesson.

The Story Wall Street Loves

SOC is built around the Santa Ynez Unit offshore California, where it has been restarting production, oil transportation, and sales after a long shutdown tied to the 2015 spill-era aftermath. The company said it began oil sales on March 29, 2026, and has outlined a phased restart across Platform Harmony, Platform Heritage, and Platform Hondo. That gives the stock a classic Wall Street setup: visible operational milestones, a finite asset base, and a narrative investors can actually model instead of merely admire from a safe distance. In other words, this is not a “story stock” in the whimsical sense; it is a story stock in the “please read the court docket before lunch” sense.

The Financial Tightrope

The capital structure matters because SOC has been funding a very expensive comeback. Recent filings and company disclosures show a refinancing push that included a concurrent equity raise and $300 million of 6.5% convertible senior notes due 2031, and roughly US$100 million of follow‑on common stock at US$3.08 per share,, a move that helps liquidity but also reminds shareholders that dilution is the house guest who never quite leaves. The company also said it planned to refinance its Senior Secured Term Loan With ExxonMobil (XOM) underscoring that SOC is trying to convert operating momentum into a more durable balance sheet. That is the kind of maneuver investors usually applaud right before they start checking how many new shares just arrived in the mail. By late June 2026, Sable amended its existing Senior Secured Term Loan with Exxon Mobil, extending the maturity to July 24, 2026 and paying a $30 million amendment fee, a move characterized as creating time and flexibility for the planned refinancing rather than closing it.

What Moves The Stock

The big swing factor is execution against restart milestones, especially because even positive operating steps have been paired with legal friction in California. Reuters reported that Sable resumed California pipeline flow under a federal order in March, while California courts later upheld state-level enforcement actions tied to the pipeline dispute. That tension is the whole trade: federal backing and production progress on one side, state litigation risk on the other. For investors, the result is a stock that can rally hard on operational progress and give it back just as quickly when the legal weather changes.

Sentiment And Valuation

Market sentiment around SOC has been mixed, with one recent sentiment snapshot leaning defensive and analyst views ranging from cautious to bullish depending on the source and timing. MarketBeat reported a consensus “Hold” among six analysts in March, while other screening services later showed a more upbeat consensus and target range, which tells you the Street still hasn’t agreed on whether SOC is a comeback kid or a cautionary tale with good lighting. The stock’s market value and share price have also been highly variable in 2026, reinforcing that this is not a sleepy E&P name. In practical terms, SOC remains a high-beta expression of one asset, one jurisdiction, and one very consequential restart plan.

Investor Takeaway

For investors who like asymmetric setups, SOC offers something rare: a concrete operating asset, a visible catalyst path, and enough controversy to keep the narrative alive. For investors who prefer calm cash flows, broad diversification, and weekends free of appellate opinions, SOC is probably not the venue. The bullish case is simple: production ramps, financing stabilizes, and the market starts valuing SOC like a functioning operator rather than a legal thriller. The bearish case is equally simple: delays, dilution, and regulatory pushback keep the story trapped between promise and paperwork.

The Sources

  1. Sable Offshore Corp. – Begins Oil Sales from the Santa Ynez Pipeline System (Official press release)
    https://sableoffshore.com/news/news-details/2026/Sable-Offshore-Corp–Begins-Oil-Sales-from-the-Santa-Ynez-Pipeline-System
  2. Sable Offshore Corp. – SEC Filings (Company financials and filings hub)
    https://sableoffshore.com/financials/sec-filings/default.aspx
  3. Sable Offshore Corp. – Corporate Update (Form 8‑K / Investor presentation excerpts)
    https://www.sec.gov/Archives/edgar/data/1831481/000183148126000037/a991ex-corporateupdatepres.htm
  4. Sable Offshore Corp. – Convertible Notes Offering (Prospectus / refinancing details)
    https://www.stocktitan.net/sec-filings/SOC/424b5-sable-offshore-corp-prospectus-supplement-debt-securities-824dfa20c1d6.html
  5. Sable Offshore Corp. Prices Offerings of Common Stock and Convertible Senior Notes (Press release)
    https://sableoffshore.com/news/news-details/2026/Sable-Offshore-Corp–Prices-Offerings-of-Common-Stock-and-Convertible-Senior-Notes
  6. Sable Offshore Corp. Reports Restart of Oil Production at Santa Ynez Unit (2025 press release)
    https://sableoffshore.com/news/news-details/2025/Sable-Offshore-Corp–Reports-Restart-of-Oil-Production-at-the-Santa-Ynez-Unit
  7. Secretary Wright Directs Sable Offshore to Restore the Santa Ynez Unit and Pipeline System (U.S. Department of Energy)
    https://www.energy.gov/articles/secretary-wright-directs-sable-offshore-restore-santa-ynez-unit-and-pipeline
  8. Sable Resumes California Oil Pipeline Flow Under Federal Order, Shares Rise (Reuters)
    https://www.reuters.com/business/energy/sable-resumes-california-oil-pipeline-flow-under-federal-order-shares-rise-2026-03-16
  9. California Appeals Court Decision – Sable Offshore Corp. v. California Coastal Commission (Published opinion)
    https://courts.ca.gov/opinion/published/2026-06-17/b347601
  10. “Gut punch for Sable Offshore as California court rules in favor of Coastal Commission on oil pipeline” (New York Post)
    https://nypost.com/2026/06/21/us-news/gut-punch-for-sable-offshore-as-california-court-rules-in-favor-of-coastal-commission-on-oil-pipeline
  11. “Sable Offshore issues battle cry after Santa Barbara judge’s ruling left California’s gas lifeline in limbo” (New York Post)
    https://nypost.com/2026/04/20/us-news/sable-offshore-issues-battle-cry-after-santa-barbara-judges-ruling-left-californias-gas-lifeline-in-limbo
  12. “Sable Offshore advances Santa Ynez output amid ongoing legal challenges” (World Oil)
    https://www.worldoil.com/news/2026/4/20/sable-offshore-advances-santa-ynez-output-amid-ongoing-legal-challenges
  13. “Sable Offshore Restarts Pipeline After Lengthy Shutdown” (National Today / local news)
    https://nationaltoday.com/us/ca/santa-barbara/news/2026/03/27/sable-offshore-restarts-pipeline-after-lengthy-shutdown
  14. Sable Offshore Corp. (SOC) – Yahoo Finance quote and news page
    https://finance.yahoo.com/quote/SOC
  15. “Sable Offshore (SOC) Is Down 42.3% After Convertible Notes And Equity Sale To Rework Exxon Loan” (Yahoo Finance article)
    https://finance.yahoo.com/markets/stocks/articles/sable-offshore-soc-down-42-090936309.html
  16. Sable Offshore (SOC) Stock Price, News & Analysis – MarketBeat
    https://www.marketbeat.com/stocks/NYSE/SOC
  17. SOC Stock Forecast: Analyst Ratings, Predictions & Price Targets – Public.com
    https://public.com/stocks/soc/forecast-price-target
  18. Sable Offshore – SOC – Stock Price & News – The Motley Fool
    https://www.fool.com/quote/nyse/soc
  19. SOC Stock Plunges As Costly Refinancing Sparks Heavy Selling – StocksToTrade / news article
    https://stockstotrade.com/news/sable-offshore-corp-soc-news-2026_07_02
  20. Sable Offshore Corp. (SOC) – CNBC quote page
    https://www.cnbc.com/quotes/SOC
5 days ago

Paging Dr. Cash Flow: Doximity Turns Clinical AI Into A Profitable House Call -( $DOCS )

Doximity Inc. (NYSE:DOCS) is quietly building one of Wall Street’s more compelling healthcare-tech narratives: a profitable, AI‑infused digital platform for U.S. clinicians that is leaning into clinical AI, telehealth, and value‑based care just as the medical establishment starts asking for them in earnest. For investors hunting for durable, cash‑generative growth in healthcare IT—with a real business today, not just a slide deck—DOCS increasingly looks less like a niche professional network and more like a core piece of the physician workflow stack.

The Set‑Up: A Profitable Platform In An AI Cost World

Doximity sits at the intersection of three secular trends: digitization of physician workflows, telehealth adoption, and the rise of clinical AI tools in day‑to‑day practice. The company is already profitable, with trailing‑twelve‑month earnings of roughly $196 million on revenue of about $645 million, translating into a healthy profit margin above 30%—a rarity in the AI‑buzzword neighborhood. Management has been candid that AI isn’t free, highlighting “AI compute costs” as a headwind to near‑term margins as DOCS ramps investment in clinical AI capabilities. Guidance for full‑year revenue in the $664–$676 million range came in below Street hopes, and investors promptly reminded the company that Wall Street, unlike physicians, does not bill by the hour. Yet the free cash flow profile—roughly $317 million in FY 2026, up nearly 20% year‑on‑year—suggests DOCS can fund those AI ambitions internally without reaching for dilutive capital.

The Last Three Signals From Management

The most recent investor communications paint a picture of a management team methodically tightening the AI and go‑to‑market screws rather than chasing the headline of the day.

  • On July 16, 2026, Doximity announced it will report fiscal 2027 first‑quarter results after market close on August 6, 2026 and host its customary investor call and webcast. The cadence reinforces a culture of consistent disclosure—unexciting on the surface, but exactly what long‑term holders want from a healthcare IT name.
  • On July 15, 2026, the company disclosed that Doximity’s clinical AI outranked OpenEvidence and several frontier models in an independent Stanford‑Harvard study focused on clinical AI safety. In an environment where “AI” can mean anything from predictive modeling to creative recipe generation, being independently validated for safety in clinical use is not just branding; it becomes a potential moat with hospitals and physician groups that think in terms of malpractice risk, not MAUs.
  • On May 21, 2026, Doximity flagged its upcoming appearance at the William Blair 46th Annual Growth Stock Conference, signaling that management is actively telling the story to the institutional growth crowd that lives and breathes forward‑multiples. For a company sitting at the crossroads of software, healthcare, and AI, that conference slot matters—it’s where incremental buyers often get their first real feel for management’s tone, discipline, and roadmap.

Taken together, these three touchpoints seem to show a team simultaneously tending to the basics (earnings visibility and conference presence) and leaning into the credibility of third‑party clinical AI validation—a combination that typically plays well in both healthcare‑IT and generalist growth portfolios.

Clinical AI: From Buzzword To Bedside

The Stanford‑Harvard study in which Doximity’s clinical AI outranked OpenEvidence and frontier models on safety is more than a nice line for the investor deck; it’s a strategic asset in a sector where “do no harm” is not a tagline but a legal standard. If you’re a hospital CIO or a large practice partner, safe clinical decision‑support is the door key; everything else—UI, mobile experience, branding—is furniture. Doximity has been systematically developing clinical AI features that slot into existing workflow rather than forcing physicians to adopt yet another standalone tool. Paired with its long‑standing telehealth video platform, which has been ranked #1 Best in KLAS for five consecutive years, DOCS is positioning its AI layer as an extension of a stack clinicians already trust. For investors, the strategic question is not whether AI will be in the exam room, but whether DOCS can be the network and tooling layer that quietly handles the traffic.

Value‑Based Care And The Aledade Partnership

On May 13, 2026, Doximity announced a partnership with Aledade to bring clinical AI into value‑based care settings. Aledade’s business model is built around enabling primary care practices to participate in value‑based contracts and improve outcomes; embedding DOCS’ clinical AI into that ecosystem gives Doximity a front‑row seat to how AI alters both clinical behavior and economics. Value‑based care lives and dies on risk adjustment, population health, and closing care gaps—all data‑heavy problems where clinical AI can be more than a shiny tool. If DOCS can demonstrate that its AI features materially improve quality metrics or reduce avoidable costs in partnership with Aledade, that becomes a compelling proof point for broader health‑system adoption and long‑tail monetization. In other words, DOCS isn’t just selling ads or sponsored content to doctors; it’s beginning to sell tangible performance in an increasingly outcomes‑driven payment world.

The Financials: Growth, Guidance, And Gravitational Pull

FY 2026 revenue of about $644.9 million grew roughly 13% year‑over‑year, with free cash flow up 19% to around $317.5 million. Net earnings of about $196 million, while down low‑double digits year‑on‑year, still reflect a robust 30%‑plus margin profile that many software‑adjacent healthcare names would envy. The guidance for fiscal 2027 implies mid‑single to low‑double‑digit top‑line growth, with AI investments weighing on margins near‑term. Some investors have responded by sharpening their pencils and reducing price targets, while others point to analyst work suggesting roughly 25–30% upside from current levels based on DOCS’ cash generation, competitive position, and growing importance of AI‑enabled clinical workflows. When a business throws off this kind of cash yet chooses to reinvest in a newly validated moat like clinical AI safety, patient investors often end up owning more than just a stock—they own an evolving category.

Risk Factors: Litigation, AI Costs, And Adoption Curves

Of course, no modern growth story is complete without its own legal subplot. On July 1, 2026, Pomerantz LLP announced an investigation into potential securities‑law claims on behalf of Doximity investors, focusing on the company’s guidance and commentary around AI‑related margin pressures. While such investigations are increasingly common around guidance resets and emerging technologies, they can inject volatility and headline risk, especially for short‑duration holders. AI compute costs remain a real economic constraint, and management has acknowledged that higher AI investment will weigh on near‑term gross margins. Meanwhile, physician adoption of AI is growing, but accuracy concerns persist; Doximity’s own research has highlighted rapid adoption tempered by understandable caution. The company’s strategy—emphasizing safety, workflow integration, and partnerships like Aledade—appears designed to ride that adoption curve rather than sprint ahead of it, but the path will likely be choppy enough to test investor conviction along the way.

The Sources

  1. Doximity, Inc. (DOCS) – Stock Price, News, Quote & History – Yahoo Finance[finance.yahoo]
  2. Doximity – Investor Relations: News (Press Releases)[investors.doximity]
  3. Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026 – Press Release[finance.yahoo]
  4. Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results – Investor Relations[investors.doximity]
  5. Doximity Outranks OpenEvidence, Frontier Models in Independent Stanford–Harvard Study of Clinical AI Safety – Investor Relations[investors.doximity]
  6. Doximity Partners with Aledade to Bring Clinical AI to Value‑Based Care Settings – Investor Relations[investors.doximity]
  7. Doximity to Present at the William Blair 46th Annual Growth Stock Conference – Investor Relations[investors.doximity]
  8. Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist – Investor Relations[investors.doximity]
  9. Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year – Investor Relations[investors.doximity]
  10. Doximity Announces Fiscal 2026 Third Quarter Financial Results – Investor Relations[investors.doximity]
  11. Doximity in the Press – Corporate Press Page[press.doximity]
  12. Doximity (DOCS) Stock Price, News & Analysis – MarketBeat[marketbeat]
  13. Doximity (DOCS) Earnings Date and Reports – MarketBeat[marketbeat]
  14. Doximity, Inc. (DOCS) Stock Report: Analyst Ratings Point to a Promising Upside[directorstalkinterviews]
  15. Doximity (DOCS) Q3 2026 Earnings Call Transcript – The Motley Fool[fool]
  16. DOCS SEC Filings – 10‑K, 10‑Q, 8‑K – StockTitan[stocktitan]
  17. Doximity Q4, FY 2026 Revenue Rises 13% – StockTitan[stocktitan]
  18. Doximity Inc (DOCS) – Google Finance[google]
  19. Doximity Inc (DOCS) – Investing.com[ca.investing]
  20. Doximity Inc (DOCS) – TradingView[tradingview]
  21. Doximity Inc. Stock Quote (DOCS) – MarketWatch[marketwatch]
  22. DOCS – Doximity Inc – Quote & Snapshot – Fidelity[digital.fidelity]
  23. Doximity (DOCS) Stock Price, Quote & Chart – Kraken[kraken]
  24. Doximity Inc. Stock – Saxo Bank[home]
  25. Earnings Call Transcript: Doximity Q3 2026 – Investing.com[investing]
  26. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Doximity Investors[newswire]

July 21, 2026

Not Your Grandfather’s Diabetes Kit: Eli Lilly’s Smart Ring Bet and Modular Medical’s Pivot Pump Rewire the Care Stack -( $LLY $MODD )

Eli Lilly and Company’s (NYSE: LLY) recent equity investment in ŌURA Health and the Oura Ring ecosystem, paired with Modular Medical’s (NASDAQ: MODD) launch of its Pivot tubeless insulin patch pump, is giving Wall Street a preview of what next‑generation metabolic care could look like when molecules, wearables, and daily routines finally start reading from the same script. The emerging narrative for investors: diabetes and obesity management are shifting from isolated prescriptions to continuous, data‑rich ecosystems—built to be clinically rigorous, but also, at long last, livable.

Lilly’s Smart Ring Move: Fingerprints on the Future of Care

Eli Lilly has taken an equity stake in ŌURA Health, maker of the Oura Ring, adding a smart, sensor‑heavy accessory to its growing cardiometabolic toolbox. With Lilly’s capital, ŌURA aims to accelerate the development of connected, personalized health tools that reflect its conviction that the future of care will be more integrated into how people actually live—sleep, move, recover, and stress—not just how they test in the clinic. ŌURA has already leaned into obesity and metabolic health, including GLP‑1 Insights, a feature designed to give users a holistic, data‑grounded view of their progress on GLP‑1 receptor agonist therapies. For Lilly—whose pipeline and portfolio are deeply tied to cardiometabolic drugs—this investment is less about a fashionable ring and more about building a digital engagement layer around its therapies, enabling better adherence, richer real‑world data, and tighter feedback loops between patient behavior and treatment outcomes. ŌURA has confirmed that Eli Lilly made an equity investment as part of its fundraising activities, including a Series E round that pushed the company toward an approximately $11 billion valuation. However, the press materials and follow‑on coverage clearly state that the size of Lilly’s stake was not detailed.

Molecules Meet Micro‑Behaviors

The Lilly–ŌURA partnership underscores a structural shift: cardiometabolic care is moving from episodic snapshots to continuous monitoring, from occasional lab values to real‑time signal analysis. Sleep quality, readiness, activity, and recovery—the core biometric domains of the Oura Ring—become inputs into a more nuanced care loop, allowing therapy decisions to be calibrated not only to weight and A1c, but to how a patient’s daily life and physiology are trending between visits. For investors, this re‑casts Lilly as not just a seller of high‑margin molecules but a participant in a broader platform play where software, hardware, and pharmaceuticals intersect. That opens optionality around digital companions for GLP‑1 and insulin therapy, AI‑powered adherence tools, and outcome‑based care models, all of which can deepen Lilly’s moat in a fiercely competitive obesity and diabetes market.

Modular Medical’s Pivot: Insulin, Made Tubeless and Tolerable

While Lilly builds out the data layer, Modular Medical is tackling a more tangible, everyday problem: making insulin pump therapy simpler to learn and less intimidating to live with via its Pivot tubeless insulin patch pump. Pivot is a removable, two‑part, fully electronic tubeless patch pump with a 3 mL reservoir, purpose‑built for adults on multiple daily injections—the “almost‑pumpers” who have hesitated to adopt traditional pumps due to complexity, cost, or lifestyle friction. Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin‑Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion‑Dollar Market, which squarely positions the product at the center of a sizeable and historically under‑served segment of diabetes technology demand.

Pivot won FDA 510(k) clearance and has begun commercial rollout, with starter kits shipping to endocrinology practices and first patients now using the system for real‑world insulin therapy. The device features intuitive, one‑button operation for bolus delivery, a flexible wearable form factor designed to support daily activities like showering and sports, and no need for battery charging, all while maintaining clinical accuracy and connectivity. By focusing on simplicity, affordability, and everyday usability, Modular Medical is positioning Pivot to expand the pump market into the large, underpenetrated universe of adults who have stayed on injections despite being clear candidates for technology‑enabled insulin delivery.

Ecosystems, Not One‑Off Trades

For investors, Lilly’s ŌURA stake signals strategic confidence in the durability of its cardiometabolic franchise and a willingness to invest around the edges of its drugs to build a more comprehensive, digitally supported care ecosystem. That ecosystem—combining GLP‑1 therapies, telehealth via LillyDirect, and behavior‑sensing wearables—can generate real‑world engagement data, strengthen payer discussions, and support differentiated patient experiences that are increasingly hard for competitors to replicate.

Modular Medical, meanwhile, offers a smaller‑cap, high‑beta expression of the same secular trend: chronic disease management is moving toward devices that are less complex and more humane, targeting an estimated majority of insulin‑dependent adults who remain on multiple daily injections. In a world where obesity and diabetes prevalence remain elevated, and where investors are hungry for scalable, patient‑centric solutions, the combination of Lilly’s data‑driven ecosystem and Modular’s practical, tubeless Pivot pump suggests that the next leg of value creation will reward companies that can make advanced therapy both clinically powerful and genuinely livable.

Takeaways

  • Eli Lilly and Company (LLY) has made an equity investment in ŌURA Health and the Oura Ring platform to accelerate connected, personalized tools for cardiometabolic care.
  • ŌURA’s GLP‑1 Insights feature aligns with Lilly’s obesity and diabetes strategy by offering users a holistic, data‑driven view of GLP‑1 therapy progress.
  • Modular Medical (MODD) has FDA‑cleared and commercially launched Pivot, a tubeless, removable insulin patch pump designed for adult “almost‑pumpers” seeking a simpler transition from multiple daily injections—and explicitly aimed at a large, multibillion‑dollar, underserved insulin‑dependent population.
  • Taken together, these moves highlight an investable trend: diabetes and obesity care are evolving into continuous, integrated ecosystems where drugs, devices, and wearables collaborate, creating long‑duration, investor‑magnetic narratives in metabolic health.

The Sources


[1] Lilly Makes an Equity Investment in Oura, Supporting … https://ouraring.com/blog/lilly-equity-investment/
[2] Modular Medical launches Pivot tubeless insulin patch pump https://www.drugdeliverybusiness.com/modular-medical-launches-pivot-tubeless-pump/
[3] Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps
[4] ŌURA and Lilly join forces to harmonise drug-wearable obesity care https://www.pharmaceutical-technology.com/newsletters/lilly-lillydirect-oura-obesity-partnership/
[5] Pivot https://pivotpump.com/
[6] Eli Lilly backs smart-ring maker Ōura in Series E to support … https://app.dealroom.co/news/note/eli-lilly-backs-smart-ring-maker-ura-in-series-e-to-support-glp-1-patients
[7] Eli Lilly makes investment in Oura for GLP-1 users https://www.linkedin.com/news/story/eli-lilly-makes-investment-in-oura-for-glp-1-users-9077226/
[8] Pivot Modular Medical’s Next‑Gen Insulin Patch Pump https://www.precedenceresearch.com/news/modular-medical-pivot-insulin-patch-pump
[9] Modular Medical announces first patients are using Pivot … https://www.hmenews.com/article/modular-medical-announces-first-patients-are-using-pivot-insulin-pump

July 20, 2026

Jerry Seinfeld’s Quiet Empire ( Now Starring Hudson Pacific Properties – $HPP )

Jerry Seinfeld has built the kind of real estate-and-collector-car portfolio that makes developers, auction houses, and REIT analysts all reach for a second espresso—and Hudson Pacific Properties, Inc. (NYSE: HPP) would likely approve of the playbook.

The Asset Class Behind The Laughs

The money story everyone knows is the sitcom engine: Seinfeld has remained a syndication machine, with reports over the years putting cumulative rerun and licensing revenue into the billions and helping lift Jerry into billionaire territory by 2026. What gets less airtime is how he translated that backend cash flow into prime bricks, dirt, and steel—an Amagansett estate in the Hamptons (acquired from Billy Joel), a Central Park-adjacent duplex on the Upper West Side, a former Telluride retreat, and Los Angeles property dating back to his TV heyday.

Why The Portfolio Works

Seinfeld’s approach to real estate is basically a high-net-worth version of a core-plus strategy: trophy locations, high-barrier-to-entry markets, and very long holding periods. That is precisely the language investors hear from institutional landlords like Hudson Pacific Properties, Inc. (HPP), a REIT focused on office and studio assets in tech-and-media epicenters where supply is constrained and tenants are sticky. Scarcity, not spectacle, is what tends to compound, whether you’re buying oceanfront in Amagansett or leased-up office towers in San Francisco.

The Garage As Balance Sheet

His car collection is not “stuff”; it’s a curated set of appreciating hard assets, dominated by historically significant Porsches and housed in a purpose-built Manhattan garage. Estimates put the collection around 150 cars, with a large share being rare Porsche models, some of which have fetched seven- and eight-figure valuations at auction or private sale, effectively turning the garage into a rolling alternative asset fund. Even the storage solution—a custom, climate-controlled, staff-supported facility—is functionally an infrastructure play for non-traditional yield.

Enter Hudson Pacific Properties (HPP)

If Seinfeld is the archetype of the quiet, scarcity-focused individual investor, Hudson Pacific Properties, Inc. (HPP) is the institutional cousin doing something similar at scale. HPP is a real estate investment trust that acquires, repositions, develops, and operates office and studio properties for tech and media tenants across high-barrier markets such as Los Angeles, the San Francisco Bay Area, Seattle, Vancouver, and Greater London. Recent company updates highlight this same scarcity-first mindset: in June 2026 Hudson Pacific executed a 502,000-square-foot, 23-year lease with the City and County of San Francisco at 1455 Market Street, effectively locking in a long-duration income stream in one of the most contested office markets in the country. Hudson Pacific has also kept investors dialed in on its fundamentals, announcing dates for quarterly earnings releases and conference calls, reflecting the transparency and cadence public-market investors expect from a REIT that bridges real estate with the content economy. For anyone watching the convergence of entertainment, office demand, and studio infrastructure, HPP is one of the few listed vehicles that turns that ecosystem into a ticker.

The Shared Playbook: Buy Scarcity, Hold Quietly

Seinfeld’s method—buy the best and hold for decades—mirrors what REITs like HPP aim to do in institutional wrapper form: concentrate capital in markets and assets that are hard to replicate, then let time, rent escalators, and tenant demand do most of the work. Where Seinfeld opts for Hamptons estates, Manhattan apartments, and a Porsche 917K, HPP leans into tech-and-media-centric office campuses and studio lots, but the underlying philosophy is similar: scarcity is the real star of the show. The comedy made Seinfeld rich; the properties and cars are what keep the wealth durable. For public-market investors, Hudson Pacific Properties, Inc. (HPP) seems to offer a way to participate in that same long-horizon, media-adjacent real estate thesis—without needing your own sitcom or Porsche vault.

Best of Jerry Seinfeld

The Sources

  1. Jerry Seinfeld Real Estate Portfolio – Realtor.com
    https://www.realtor.com/news/celebrity-real-estate/jerry-seinfeld-real-estate-portfolio/
  2. Jerry Seinfeld – Biography and Career Overview (Wikipedia)
    https://en.wikipedia.org/wiki/Jerry_Seinfeld
  3. Inside Jerry Seinfeld’s Car Collection – Torque Cafe
    https://torquecafe.com/inside-jerry-seinfelds-car-collection/
  4. Take a Closer Look at Jerry Seinfeld’s Car Collection – CarBuzz
    https://carbuzz.com/features/take-a-closer-look-at-jerry-seinfelds-car-collection/
  5. Jerry Seinfeld’s Porsche Collection Is Phenomenal – GQ
    https://www.gq-magazine.co.uk/cars/article/jerry-seinfeld-porsche-collection[
  6. Jerry Seinfeld Net Worth 2026: Sitcom Legend’s Billionaire Status – Koimoi
    https://www.koimoi.com/fashion-lifestyle/jerry-seinfeld-net-worth-2026-how-a-sitcom-legend-built-a-1-1b-fortune/
  7. Jerry Seinfeld Real-Time Net Worth Profile – Forbes
    https://www.forbes.com/profile/jerry-seinfeld/
  8. Seinfeld Syndication Revenue and Franchise Economics – The Independent
    https://www.independent.co.uk/arts-entertainment/comedy/news/seinfeld-is-laughing-all-the-way-to-the-bank-tv-show-generates-3-1bn
  9. Jerry Seinfeld Says It’s Never Been About the Money – Yahoo Entertainment
    https://www.yahoo.com/entertainment/tv/articles/jerry-seinfeld-says-money-never-194612239.html
  10. Hudson Pacific Properties, Inc. (HPP) – Yahoo Finance Quote Page
    https://finance.yahoo.com/quote/HPP/
  11. Hudson Pacific Properties, Inc. (HPP) – Company Overview and Quotes – CNBC
    https://www.cnbc.com/quotes/HPP
  12. Hudson Pacific Properties, Inc. – Investor Resources and Press Releases
    https://investors.hudsonpacificproperties.com/investor-resources/press-releases/
  13. Hudson Pacific Executes 502,000-Square-Foot, 23-Year Lease at 1455 Market – Business Wire
    https://www.businesswire.com/news/home/20260611462208/en/Hudson-Pacific-Executes-502000-Square-Foot-23-Year-Lease-with-City-and-County-of-San-Francisco-at-1455-Market
  14. Hudson Pacific Properties Announces Date for Second Quarter Earnings Release and Call
    https://investors.hudsonpacificproperties.com/investor-resources/press-releases/press-release-details/2026/Hudson-Pacific-Properties-Announces-Date-for-Second-Quarter-Earnings-Release-and-Conference-Call[investors.hudsonpacificproperties]
  15. Hudson Pacific Properties (HPP) – Stock Price, News & Analysis – Seeking Alpha
    https://seekingalpha.com/symbol/HPP[seekingalpha]
  16. Hudson Pacific Properties Inc. – Stock Quote and Company Snapshot – MarketWatch
    https://www.marketwatch.com/investing/stock/hpp
  17. Hudson Pacific Properties Inc. – Stock Price Quote – Morningstar
    https://www.morningstar.com/stocks/xnys/hpp/quote
July 20, 2026

AI Trade Pauses, Oil Climbs, AMC Surges: What Drove the S&P 500 Lower Today – July 20, 2026 -( $AMC $CNK $DOCS $IMAX $NVDA Rise!)

US equities traded somewhat mixed to lower on Monday, July 20, 2026, as investors balanced rising oil prices, an AI-led factor rotation, and mounting anticipation around upcoming Big Tech earnings. The S&P 500 slipped modestly while the Dow underperformed and the Nasdaq essentially marked time, even as select chip and AI names stabilized after last week’s sharp drawdown.

Index recap and risk tone

Wall Street delivered a subdued session characterized by tight intraday ranges and a modest risk-off tilt under the surface. The S&P 500 Index (^GSPC) fell roughly 0.1–0.2%, coming off just its third down week since late March, signaling fatigue rather than outright de-risking at the benchmark level. The Dow Jones Industrial Average (^DJI) declined around 0.5–0.6%, while the Nasdaq Composite (^IXIC) was nearly unchanged, finishing down less than 0.1% as large-cap growth steadied. Small caps bore the brunt of selling pressure, with the Russell 2000 (^RUT) dropping about 0.7%, an extension of a recent pattern in which higher yields and tighter financial conditions weigh more heavily on domestically focused and lower-quality balance sheets. Despite Monday’s softness, the S&P 500 remains up roughly 8–9% year-to-date, the Dow about 8%, and the Nasdaq nearly 10%, underscoring that the primary trend is still higher even as day-to-day leadership grows more fragmented.

Macro and commodities: oil back in the driver’s seat

Macroeconomic sentiment was dominated by energy and geopolitics as oil’s grind higher increasingly reasserts itself as a key cross-asset driver. Brent crude (BZ=F) pushed higher again after briefly easing, rebounding toward the 90-dollar area following tit-for-tat military actions involving the United States and Iran and heightened tensions around shipping in the Strait of Hormuz. Houthi militants’ declaration of a “maritime embargo” against Saudi Arabia is raising concerns about potential chokepoints in global crude flows, even as futures prices remain below their April–May peaks, suggesting markets still assume some rerouting capacity and supply flexibility. Higher oil prices are feeding directly into Treasury yields, which continued to edge up on Monday and added incremental pressure on rate-sensitive equities, including small caps and more leveraged cyclicals. For equity investors, the macro setup remains a balancing act: on one side, resilient growth and robust nominal demand support earnings, especially in energy and select cyclicals; on the other, the combination of higher input costs and elevated real yields tightens financial conditions at the margin and raises the hurdle rate for long-duration growth stories.

AI, semis, and the Big Tech earnings overhang

The AI trade spent the day searching for a new catalyst rather than cascading lower, as leading semiconductor and AI-adjacent names stabilized after last week’s valuation-driven shakeout. Chip stocks broadly firmed, helping keep the Nasdaq near flat even as broader indices drifted lower, a sign that investors are selectively re-engaging after forced or risk-managed de-risking in prior sessions. Yet sentiment remains fragile, with an ongoing global reassessment of stretched AI valuations evidenced by steep drawdowns in some Asia-Pacific benchmarks and AI-linked names, including the nearly 4.5% selloff in South Korea’s Kospi as local investors trimmed high-flying AI exposures.

Heading into the heart of earnings season, the market’s focus is squarely on whether mega-cap platforms can convert AI narratives into tangible monetization. Street expectations have been ratcheted higher for Alphabet Inc. (GOOG, GOOGL), Intel Corporation (INTC), International Business Machines Corporation (IBM), and Tesla Inc. (TSLA), with investors looking for evidence that capex-heavy AI build-outs are now unlocking incremental revenue, margin expansion, or durable ecosystem advantages. The bar is now meaningfully higher for forward guidance: commentary around AI workloads, cloud optimization, inference demand, and data-center efficiency is likely to matter as much as headline EPS beats or misses.

Single‑stock spotlight: AMC’s fundamental comeback

AMC Entertainment Holdings Inc. (AMC) emerged as a high-beta outperformer, with shares surging more than 11% intraday and opening above 2 dollars as the theater chain delivered its strongest quarter in company history. The company reported second-quarter 2026 adjusted earnings of 0.14 dollars per share, dramatically outperforming consensus expectations that had called for a 0.04 dollar loss, as both top line and profitability surprised to the upside. Revenue climbed 14% year over year to 1.59 billion dollars, ahead of the 1.5 billion dollar Wall Street forecast, while adjusted EBITDA jumped 70% to roughly 321.4 million dollars, surpassing the 300 million dollar mark for the first time and underscoring operating leverage as attendance improves. Management highlighted that more than 4.3 million moviegoers visited AMC’s U.S. AMC Theatres and international ODEON circuits over the Thursday–Sunday window, driven by the record-shattering opening of Christopher Nolan’s “The Odyssey,” produced and distributed by Universal Pictures, a division of Comcast Corporation (CMCSA). “The Odyssey” generated an estimated 124.5 million dollars in domestic box office and 139.6 million dollars internationally for a global debut of roughly 264.1 million dollars, marking the strongest opening weekend of Nolan’s career and delivering AMC its biggest R-rated opening across its U.S. circuit since 2024. In sympathy, IMAX Corporation (IMAX) gained around 3.2% and Cinemark Holdings Inc. (CNK) rose about 3.6%, illustrating how a robust tentpole slate can lift the broader exhibition complex even as AMC’s equity remains nearly 99% below its 2021 meme-stock peak.

Takeaways for investors and content positioning

From an investor’s lens, Monday’s tape reinforces several themes: macro remains dominated by energy and geopolitics; AI is transitioning from pure narrative to proof-of-monetization; and pockets of the real economy—such as theatrical exhibition via AMC, IMAX, and CNK—are quietly demonstrating cyclical recovery and operating leverage. For institutional allocators, the setup argues for maintaining a barbelled posture: pairing quality growth exposure in AI and cloud platforms like GOOG, GOOGL, INTC, IBM, and TSLA with selective cyclicals and energy, while remaining wary of the drag from higher real yields on small caps and lower-quality balance sheets.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.58.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $14.75) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.24) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.64), a leader in innovative, patient-centric insulin delivery, released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $6.69), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $203.28, +.23%.

The InterGroup Corporation (INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $38.60.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.19) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.52), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $21.73, +.98% is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

The Sources


[1] Stock market today: Dow, S&P 500, Nasdaq mixed as oil rises, Big Tech earnings loom https://finance.yahoo.com/markets/live/stock-market-today-monday-july-20-dow-sp-500-nasdaq-oil-111429441.html
[2] How major US stock indexes fared Monday 7/20/2026 https://www.seattletimes.com/business/how-major-us-stock-indexes-fared-monday-7-20-2026/
[3] World shares are mixed and South Korea’s Kospi drops 4.5% as some AI stocks swoon https://www.mysanantonio.com/news/world/article/south-korea-s-kospi-drops-nearly-5-as-some-ai-22351788.php
[4] Asia stocks mixed as investors reassess AI bets; S Korea slides, China outperforms By Investing.com https://uk.investing.com/news/stock-market-news/asia-stocks-mixed-as-investors-reassess-ai-bets-s-korea-slides-china-outperforms-4777205?ampMode=1
[5] AMC Stock Soars On Earnings And The Odyssey https://www.youtube.com/watch?v=QeHwtKNFBnU
[6] Stock market today: Dow, S&P 500, Nasdaq mixed as chip stocks rise in wait for Big Tech earnings https://finance.yahoo.com/markets/live/stock-market-today-monday-july-20-dow-sp-500-nasdaq-111429441.html
[7] US Markets Open Mixed; Chip Stocks Recover Small Fraction of AI Loss https://ts2.tech/en/us-markets-open-mixed-chip-stocks-recover-small-fraction-of-ai-loss/
[8] Europe close: Stocks mixed as investors watch oil markets https://www.sharecast.com/news/market-report-europe-close/europe-close-stocks-mixed-as-investors-watch-oil-markets–23073354.html
[9] World shares are mixed and South Korea’s Kospi drops 4.5% as some AI stocks swoon https://www.mcalesternews.com/region/world-shares-are-mixed-and-south-koreas-kospi-drops-4-5-as-some-ai-stocks/article_a0f878f7-d1d9-5652-a77d-e2d06d1ec5ed.html
[10] Stock Market Today: Live Updates 20.07.2026 https://ts2.tech/en/stock-market-today-20-07-2026/
[11] Asian markets mixed as AI selloff deepens; South Korea’s Kospi slides nearly 5% https://www.emirates247.com/business/asian-markets-mixed-as-ai-selloff-deepens-south-koreas-kospi-slides-nearly-5/3788
[12] Stock Market Today (July 20, 2026): S&P 500 climbs as U.S. … https://www.thestreet.com/stock-market-today/stock-market-today-dow-jones-sp-500-nasdaq-updates-july-20-2026

July 20, 2026

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in terms of Dupixent’s legacy in the indication.

Setting the Scene: A Small Cap Meets a Big Catalyst

Eupraxia Pharmaceuticals has spent much of the past year moving from relative obscurity into the institutional conversation, helped by a growing chorus of inbounds as the market digests the upcoming Phase 2b RESOLVE trial readout for EP‑104GI, an extended‑release formulation of fluticasone propionate designed for EoE. The company currently carries an Overweight rating and a $19 price target at Cantor Fitzgerald, versus a recent share price of $6.32 and a 52‑week range of $4.88 to $9.32, leaving meaningful room for rerating if the December data clear investors’ efficacy and durability thresholds. With a roughly 65 million share count and no product revenue yet, but with cash that Eupraxia believes will be sufficient to fund the Company into the second half of 2028, EPRX remains a quintessential clinical‑stage story whose value will increasingly be driven by trial design, endpoint literacy, and how its data stack up against a well‑entrenched competitor.

The EoE Problem: When Swallowing Becomes a Negotiation

Eosinophilic esophagitis has quietly evolved from a niche diagnosis into a defined therapeutic market, driven by rising prevalence, better recognition and, frankly, patients who would prefer not to negotiate every meal with their esophagus. Clinicians rely on an alphabet soup of tools to quantify the disease: the EoE Histology Scoring System (EoEHSS) to grade severity and stage the extent of eosinophilic infiltration, Peak Eosinophil Counts (PEC) to track raw inflammatory burden, and the Endoscopic Reference Score (EREFS) to describe what the esophagus actually looks like under the scope. On the patient side of the ledger, dysphagia symptom instruments such as the Straumann Dysphagia Index (SDI) and Dysphagia Symptom Questionnaire (DSQ) attempt to translate difficulty swallowing into something more reproducible than “this feels terrible.”

EP‑104GI: Engineering A Once‑And‑Done Esophageal Steroid

At the center of Eupraxia’s story is EP‑104GI, a long‑acting corticosteroid formulation intended to deliver sustained fluticasone exposure locally to the esophagus, with the goal of reducing inflammation while minimizing systemic steroid baggage. In the Phase 1b/2a program, EP‑104GI has already demonstrated histologic and endoscopic signal, with changes in EoEHSS grade and stage scores on a 0‑1 scale of roughly −0.38 in Cohort 8b and up to −0.57 and −0.63 in Cohort 9 at Week 12, alongside an improvement in EREFS scores on a 0‑9 scale of −5.0 and −4.0 in those respective cohorts. Patients reported better swallowing function as well, with SDI PRO scores improving by −3.67 and −2.33 at Week 12 and deepening to −6.00 and −4.00 by Week 24 in Cohorts 8b and 9, respectively, underscoring a trajectory that seems to favor both mucosal healing and symptom relief over time.

The RESOLVE Blueprint: 52 Weeks to Convince the Street

If Phase 1b/2a established that EP‑104GI can move the right needles, the RESOLVE Phase 2b study was deliberately engineered to test how far and how durably those needles can move in a real‑world‑like population. The trial enrolls approximately 120 adult EoE patients and follows them for 52 weeks, randomizing them 1:1:1 to placebo, EP‑104GI Dose A (20 injections of 6 mg) or Dose B (20 injections of 8 mg), with the placebo arm crossing over to active treatment after 24 weeks. Esophagogastroduodenoscopy (EGD) is performed at Weeks 0, 12, 24, 36 and 52, with patient‑reported outcomes captured at multiple interim timepoints, positioning RESOLVE to deliver not just a snapshot, but a time‑lapse of inflammation, remodeling and dysphagia over the course of a year.

The Bar: Dupixent, Regeneron/Sanofi and the Art of Cross‑Trial Comparisons

In the current EoE landscape, most investors intuitively measure new entrants against Dupixent, the Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)/Sanofi (NASDAQ: SNY) monoclonal antibody that has set a high bar in multiple age cohorts. In adult and adolescent trials such as NCT03633617 and NCT02379052, weekly Dupixent 300 mg injections have shown robust histologic improvements, with converted EoEHSS grade and stage scores on a 0‑1 scale improving by about −0.277 and −0.268 at Week 24 versus placebo changes of −0.05 and −0.044, implying placebo‑adjusted effects of roughly −0.227 and −0.224. Endoscopic EREFS scores also moved convincingly, with a placebo‑adjusted reduction of about −2.0 on a 0‑9 scale at 24 weeks, and DSQ symptom scores improving by nearly −23.8 versus −13.9 for placebo, yielding a placebo‑adjusted differential just shy of −10 points. That said, the comparison game requires more nuance than simply lining up bars on a chart, as REGN’s studies often use an EoEHSS 0‑3 scale that must be converted to EPRX’s 0‑1 framework and EREFS may be scored as high as 0‑18 when proximal and distal segments are tallied separately. Cantor’s deep dive consolidates these moving parts into a single reference set, acknowledging both Dupixent’s impressive track record and the danger of over‑interpreting cross‑trial data that differ by scale, timing and population. For Eupraxia, the practical takeaway is clear: December’s Phase 2b data do not need to out‑perform Dupixent line‑for‑line to be viewed positively, but they do need to land in the same neighborhood on key endpoints, with a differentiated delivery profile and a development path that investors can underwrite.

What EP‑104GI Has Shown So Far: PEC, Histology and Symptom Trajectories

From an inflammatory standpoint, EP‑104GI has already delivered compelling early signals in Peak Eosinophil Counts, a more brute‑force way of quantifying esophageal eosinophilia. In Cohort 8b, percent reductions in PEC from baseline have reached approximately −65% by Week 12 and maintained around −72% by Week 36, while Cohort 9 has dipped to roughly −75% at Week 12 and −72% by Week 36 after 20 injections of 8 mg per dose, suggesting sustained suppression rather than a short‑lived pharmacologic haircut. For context, Dupixent trials have reported PEC reductions at various timepoints in the −71% to −80% range in adult populations, with long‑term follow‑up demonstrating continued improvements over 52 and even 100 weeks, reinforcing why the Street views EP‑104GI’s inflammation profile as “maturing toward” a known benchmark rather than reinventing the wheel. The histology story, as captured by EoEHSS, adds another layer of differentiation, because this scoring system explicitly separates grade (severity) and stage (extent) across multiple esophageal sites. EoEHSS captures features ranging from eosinophil density to architectural changes, with scoring systems that can be either 0‑1 or 0‑3 for individual components, necessitating careful conversion when comparing across trials. EP‑104GI’s early performance on the 0‑1 scale, with grade and stage reductions in the −0.38 to −0.63 range at Week 12, suggests meaningful improvements in both how bad and how widespread the disease looks under the microscope, an encouraging signal for a once‑and‑done steroid strategy that aims to keep pathologists and patients equally satisfied.

Endoscopes and Esophagi: Making Sense of EREFS

While histology answers the question “what does the tissue look like under high magnification,” EREFS answers the more pragmatic question of “what does the esophagus look like when a gastroenterologist threads a scope down and takes stock.” The Endoscopic Reference Score dissects five features—edema, rings, exudates, furrows and strictures—and assigns scores based on presence and severity, with total scores ranging from 0‑8 or 0‑9 for the entire esophagus and potentially doubling to 0‑16 or 0‑18 when proximal and distal segments are assessed separately. Edema and exudates speak to active inflammation, furrows reflect uneven inflammatory tracks, and rings and strictures flag advanced fibrosis that can translate directly into dysphagia and, in severe cases, mechanical obstruction. Eupraxia’s EP‑104GI has already demonstrated multi‑point improvements here, with EREFS score reductions of −5.0 and −4.0 on a 0‑9 scale at Week 12 across its early cohorts, which represents a broad‑based easing of inflammatory and fibrotic features rather than a cosmetic touch‑up in a single domain. For investors, EREFS offers a bridge between biomarker‑rich histology tables and the clinical narrative: fewer rings and strictures suggest less remodeling, which in turn supports the argument that sustained steroid exposure via EP‑104GI could slow progression toward more severe disease states. That bridge matters when the Street weighs whether a once‑annual steroid implant can meaningfully compete with a systemic biologic on endoscopic outcomes that physicians use every day.

Putting Patients Back at the Center: SDI, DSQ and EoE‑IQ

Biotech investors love a good biomarker, but payers and regulators increasingly insist that improvements in slides and scopes translate into meaningful day‑to‑day relief. Here, EP‑104GI’s performance on patient‑reported outcomes such as the Straumann Dysphagia Index and Dysphagia Symptom Questionnaire has quietly strengthened the story, with SDI scores improving by several points in the first three months and continuing to deepen through six months in early cohorts. These instruments attempt to quantify how often patients struggle with swallowing, how severe those episodes are, and how much EoE disrupts daily life, providing a more human complement to PEC and EoEHSS while giving the FDA and payers metrics they can readily evaluate. The broader field has also introduced composite tools like the EoE‑IQ, which aim to integrate various symptom and quality‑of‑life measures into a more holistic view of disease burden. Cantor’s framework in its deep dive maps out what constitutes clinically meaningful change on these scales and highlights how EP‑104GI’s trajectory could read if December data confirm or extend prior improvements. For Wall Street, these instruments serve as early indicators of whether a product can justify premium pricing and capture formulary support, helping investors imagine not just approvability, but real‑world uptake.

Timelines, Catalysts and the Regulatory Path

Beyond the December Phase 2b data, Eupraxia has sketched a development path that offers investors a series of definable catalysts rather than a single binary event. Additional RESOLVE data may emerge next year as more patients reach the one‑year mark and the placebo crossover cohort matures, providing extended views on durability, dose optimization and safety. The company intends to hold an End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration in the first half of 2027, with a plan to launch a single registrational Phase 3 study in mid‑2027, a streamlined approach that reflects confidence in the Phase 2b design and in the robustness of the endpoints selected. Cantor’s preview also hints at a follow‑up “Part 2” analysis that will dive into baseline characteristics from RESOLVE and compare patient profiles in Eupraxia’s trials to those in Regeneron/Sanofi’s Dupixent program. For investors, that kind of cross‑study demystification can be pivotal, particularly in a disease where endpoint scales can be deceptively similar while hiding meaningful differences in scoring systems and patient mix. The net effect is a clear catalyst map that stretches from December 2026 through 2027, allowing both fundamental and catalyst‑driven investors to plan positioning rather than treating EPRX as a one‑headline story.

Why Wall Street Is Paying Attention Now

In the months leading up to December, inbound interest in Eupraxia has reportedly increased notably, as investors seek centralized, digestible data on Dupixent’s performance across histologic, endoscopic and symptom endpoints to approximate the bar EP‑104GI will be judged against. Cantor’s report explicitly positions EPRX as a Top Pick and recommends buying the stock ahead of the Phase 2b readout, arguing that awareness has improved and that the risk‑reward skews favorably if December data come in at least in line with Dupixent’s performance on key measures. For a small‑cap biotech with no revenue, that kind of pre‑data conviction in a high‑bar indication is unusual—and it tends to attract both specialist and generalist capital, especially when the underlying disease is increasingly recognized and the control arm is a widely used biologic. The complexity of EoE endpoints also plays to Eupraxia’s advantage, in a counter‑intuitive way. By investing heavily in educating the Street on how EoEHSS, PEC, EREFS, DSQ, SDI and EoE‑IQ are constructed and interpreted, Cantor and the company are effectively raising the conversation from anecdotal comparisons to discipline, which can reduce knee‑jerk reactions when top‑line numbers hit the tape. In a market that has learned to be skeptical of “non‑head‑to‑head” claims, a cleaner, better‑explained dataset can be a differentiator all its own.

Investor Takeaways: What Needs to Go Right

Heading into December, several themes appear central to how EPRX is likely to trade around EP‑104GI’s Phase 2b readout.

  • Histology: EoEHSS grade and stage scores on a 0‑1 scale need to demonstrate improvements that approximate Dupixent’s converted 0‑1 data, with both severity and tissue involvement meaningfully reduced over 24–52 weeks.
  • Inflammation: PEC reductions in the −70% range at key timepoints would support the narrative that EP‑104GI meaningfully suppresses eosinophilic burden in line with established biologic benchmarks.
  • Endoscopy: EREFS improvements must show broad‑based reductions in edema, exudates, furrows, rings and strictures, reinforcing both anti‑inflammatory and anti‑fibrotic benefits that clinicians can see on screen.
  • Symptoms: SDI and DSQ trajectories should confirm that histologic and endoscopic gains are translating into fewer and less severe dysphagia episodes, supporting payer and regulatory confidence.
  • Safety and convenience: EP‑104GI’s extended‑release, procedure‑based administration must deliver a tolerability and convenience profile that can engage patients and physicians who may be reluctant to commit to chronic systemic biologic therapy.

If Eupraxia can deliver on this multi‑dimensional checklist, investors may find themselves re‑rating EPRX not simply as an EoE “me‑too,” but as a potentially complementary or alternative platform in a market that is far from saturated. In that scenario, the December data would mark not the end of the story, but the beginning of a new chapter in which EP‑104GI joins Dupixent as part of a broader toolkit for managing a chronic, life‑disrupting disease—and EPRX graduates from an under‑followed small cap to a mid‑cap contender with definable growth optionality.

The Sources

  1. Cantor Fitzgerald Deep Dive on Eupraxia / EoE “Bar” Contact your local Cantor Fitzgerald branch to receive a copy.
  2. Eupraxia Pharmaceuticals – Positive Tissue Health Update / SPRINGBOARD Phase 2b
    – Eupraxia Pharmaceuticals Reports Positive Tissue Health …
  3. Eupraxia Pharmaceuticals – RESOLVE Phase 1b/2a Trial Data in EoE
    – Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP‑104GI for Treatment of Eosinophilic Esophagitis
  4. Initial Results from RESOLVE – Scientific Poster (ISDE)
    – Initial Results from RESOLVE, a Phase 1b/2a Dose‑Escalation Study of EP‑104GI (Extended‑Release Fluticasone Propionate Intra‑Esophageal Injection) for Eosinophilic Esophagitis – Poster PDF
  5. DDW 2026 – RESOLVE Study Design Overview
    – RESOLVE: A Phase 1b/2 Study Evaluating the … (Design PDF)
  6. AppliedXL Coverage – EP‑104GI Facing H2 2026 Test
    – Eupraxia’s EP‑104GI faces H2 2026 test after early EoE injections showed 65% EREFS gains
  7. ACG / DDW Abstract – Efficacy and PK Results from Ongoing Dose Escalation
    – P3911 – Efficacy and Pharmacokinetic Results From Ongoing Dose‑Escalation Study of EP‑104GI for EoE
  8. Oxford Academic – Early Clinical Results from RESOLVE
    – 265. INITIAL RESULTS FROM RESOLVE, A PHASE 1B DOSE‑ESCALATION STUDY OF EP‑104GI …
  9. Investing.com – Eupraxia Progress in EoE Trial
    – Eupraxia reports progress in EoE drug trial with promising results
  10. Investing.com – Cantor Fitzgerald Overweight Rating on EPRX
    – Cantor Fitzgerald reiterates Overweight rating on Eupraxia stock at $11[ca.investing]
  11. Investing.com – Raymond James Strong Buy Rating on EPRX
    – Eupraxia Pharmaceuticals stock rating reiterated at Raymond James[investing]
  12. StockTitan – Aggregated News on EPRX
    – Eupraxia Pharmac (EPRX) Stock News & Updates | StockTitan
  13. Regeneron/Sanofi – Dupixent EoE Efficacy Page (Adult/Adolescent)
    – Efficacy in EoE | DUPIXENT (dupilumab)
  14. Sanofi Press Release – Dupixent EoE Trial Meets Endpoints
    – Dupixent (dupilumab) eosinophilic esophagitis trial meets both co‑primary endpoints
  15. Mackie Research – Cashed Up for Potential Best‑in‑Class EoE Therapy (EPRX)
    – Cashed Up For A Potential Best‑In‑Class EoE Therapy (PDF)
  16. Eupraxia Investor News – Nine‑Month Tissue Health / Cohort Data
    – Release Details – Eupraxia Pharmaceuticals Reports Positive Nine‑Month Tissue Health …m

July 19, 2026

AI’s New Memory Wall: Why Investors Are Piling Into the Brains Behind the Boom -( $AVGO $META $MU $NVDA $SKHY $SMWB $STX )

Wall Street has finally found something that can make even the most swaggering AI GPU look nervous: the memory wall. The very chips designed to feed artificial intelligence its endless diet of data are hitting physical, economic, and manufacturing limits—and the result is a new kind of scarcity story that investors are only beginning to price in. In this cycle, the bottleneck isn’t how fast you can compute; it’s how much you can remember at once, how quickly you can move that information, and how many terabytes per second you can reasonably afford. Memory has gone from supporting actor to leading role in the AI economy, with DRAM and high-bandwidth memory (HBM) now dictating everything from training timelines to smartphone prices.

The Memory Crunch: Bigger, Meaner, and More Profitable

Veterans of the semiconductor industry have seen cycles before, but this one comes with extra caffeine. DRAM contract prices are projected to jump more than 58%–63% quarter over quarter—one of the steepest moves in a decade—while leading producers report pricing up as much as 90% in a single quarter. Servers now account for roughly 60%–70% of global memory demand, up from about 30% before the AI wave, turning data centers into the gravitational center of the memory universe. The three dominant HBM players—Samsung Electronics, SK hynix, and Micron Technology (NASDAQ: MU)—have reallocated capacity toward their most profitable AI products, leaving consumer DRAM supply looking more like an afterthought than a growth engine. The upshot is that memory chips—once the unassuming workhorses of PCs and smartphones—have become “the most valuable commodity in the AI economy,” with index-level moves and single-stock surges that would make a meme stock blush.

Wall Street Learns to Love the “Plumbing”

For years, memory was treated as cyclical plumbing: necessary, boring, and perennially late to the party. Not anymore. Recent commentary from executives and analysts suggests that AI workloads have permanently altered the supply–demand dynamic. Hyperscalers are locking in multi-year supply agreements that stretch into 2028, a sharp departure from the one-year cadence that once defined the industry. CEOs now casually reference securing memory capacity as far out as three years, turning long-term contracts into a form of financial armor against AI volatility. From an investor’s lens, that means revenue visibility is improving just as pricing power inflects higher—an unusually friendly pairing for a sector historically known for boom-bust déjà vu. If memory used to be a “trade,” AI is actively lobbying to make it a “theme.”

The Consumer Squeeze: Smartphones Pay for the AI Party

Every bull market needs a straight man, and in this story the role is played by your smartphone. As capacity is diverted to HBM and server-grade DRAM, consumer devices are now competing directly with AI inferencing GPUs for the same memory pool. Analysts are already flagging record-high smartphone prices and double-digit volume declines as smaller Android manufacturers get squeezed out of the supply chain. Device makers are being forced into uncomfortable choices: ship phones with less memory, raise prices, or retreat to the high end and pray their customers don’t notice. Meanwhile, flagship brands with deep pockets—think Apple and Samsung—are positioned to consolidate share, having the financial and strategic muscle to secure long-term contracts in a way smaller rivals simply cannot. For investors, that’s a reminder: AI’s upside in chips can ripple into consumer tech in ways that reward scale and punish fragility.

AI Memory Chips by the Numbers

The AI memory chip market itself is no longer a niche line item in a semiconductor report; it’s a growth engine in its own right. Global AI memory chip revenue is projected to rise from about $14.8 billion in 2026 to roughly $45.6 billion by 2034, implying a compound annual growth rate north of 16%. That growth is powered by three converging themes: edge computing, cloud training, and autonomous systems in sectors like automotive and healthcare. Generative AI models, with their appetite for massive parallel processing and huge parameter counts, are driving demand for higher bandwidth and lower latency across the memory stack. In practical terms, each architectural leap in AI—from recommendation engines to foundation models—requires a corresponding upgrade in memory density, throughput, and efficiency. Investors who once focused solely on GPUs now have to follow the entire data path, from processor to memory channel, if they want the full picture.

Key Players in the New AI Memory Stack

SegmentExample companies / tickersRole in AI memory story
DRAM / HBM producersSamsung (KRX: 005930), SK hynix (SKHY), Micron Technology (NASDAQ: MU)Supply AI training and inference memory; core beneficiaries of pricing power
AI acceleratorsNVIDIA (NASDAQ: NVDA), Meta Platforms (NASDAQ: META)Drive demand for high-bandwidth memory and new architectures.
Storage / HDDSeagate Technology (NASDAQ: STX)Feels knock-on effects of memory pricing and long-term contract shift.\
Hyperscalers / cloudBroadcom’s major clients (NASDAQ: AVGO mentioned as a supplier), hyperscale buyersLock in multi-year supply, reshaping cycle dynamics.

Memory, Meet Data: Why Similarweb (SMWB) Matters

Amid the scramble for physical bits of memory, there’s a parallel race for digital signals—the kind that reveal who is winning the online battle for users, attention, and revenue. This is where Similarweb Ltd. (NYSE: SMWB) enters the investor conversation. Similarweb operates a platform that lets users analyze companies’ markets, audiences, and digital footprints, including traffic trends, stock performance signals, and engagement metrics over multi-year periods. Investors can use such tools to spot inflection points in demand, identify rising competitors, and validate whether AI narratives are actually translating into real-world digital traction. In an AI-driven economy where memory chips are scarce and capital is abundant, the ability to measure digital behavior—who is gaining share, who is losing engagement, who is quietly compounding traffic—becomes its own kind of alpha source. SMWB is not selling DRAM or HBM; it’s selling context, which investors increasingly need if they want to distinguish durable trends from beautifully told bubbles.

From Cycle to Structure: What This Means for Investors

The most important shift for investors is conceptual: memory is moving from a cyclical commodity to a structural bottleneck in AI infrastructure. New fabs from Samsung, SK hynix, Micron, and Kioxia will take years to come online, with major capacity additions not expected to hit full stride until 2027–2028. That leaves several years where demand growth is likely to outpace incremental supply, a rare setup in a historically oversupplied segment. As hyperscalers sign long-term contracts and AI models compound in size, the “wall” that limits progress is less about the next clever algorithm and more about sustained access to high-performance memory at scale. This has implications for everything from margin structure at chipmakers to capital allocation at cloud providers and device OEMs.

For portfolio construction, it suggests three working hypotheses:

  • Memory producers with HBM leadership and disciplined capacity adds could enjoy extended pricing power.
  • Downstream device makers face margin pressure and potential consolidation as consumer memory gets repriced by AI demand.
  • Data and analytics platforms like Similarweb (SMWB) gain strategic relevance as investors seek differentiated signals beyond price charts and press releases.

In other words, the AI trade is no longer just betting on which GPU wins the benchmark race; it’s about understanding the entire stack—from transistors and memory cells to data flows and user behavior—and then positioning capital where structural scarcity and measurable demand intersect. If the memory wall is getting taller, the market is quietly telling investors to back those building the ladders—and those providing the maps.

The Sources

Sources

  1. The AI ‘Memory Wall’ Is About to Get a Lot Taller: These 3 Stocks Will Win Big — Yahoo Finance/24/7 Wall St.
  2. Wall Street thinks memory is AI’s golden ticket — Fortune
  3. AI Server Demand to Drive Memory Contract Price Increases in 2Q26 — TrendForce
  4. DRAM prices predicted to jump 63% in Q2, NAND up to 75% — Tom’s Hardware
  5. AI Memory Chip Market 2026–2034 — Intel Market Research
  6. AI is gobbling up the world’s memory chips, sending smartphone prices to record highs — CNN
  7. AI Chip Manufacturing Demand Creates Historic Shortage — Bloomberg
  8. Rise in memory chip costs puts pressure on retailers of laptops and smartphones — CNBC
July 19, 2026

Apple Out-AI’s the AI Darlings: Why $AAPL Is Quietly Schooling $NVDA on Market-Cap Math

Apple Inc. (NASDAQ: AAPL) has just turned a familiar mega-cap narrative into an investor magnet, reclaiming the mantle of the world’s most valuable company while quietly proving that the most durable AI trade might be hiding in plain sight—in your iPhone, your subscriptions, and your dividend checks.

Apple’s Quiet AI Upside: From “Phone Stock” to Market-Cap Titan

Apple has reclaimed the top spot in global market capitalization, edging past Nvidia Corporation (NASDAQ: NVDA) with a valuation around the high single-digit trillions, as Nvidia’s shares slipped on renewed scrutiny of AI-driven valuations. For investors, this is not a mere leaderboard reshuffle; it is a signal that capital is rotating toward companies that marry AI relevance with durable cash-flow generation and disciplined capital returns.

The fiscal 2026 second quarter underscored Apple’s operating strength: double‑digit revenue growth, strong EPS expansion, and tens of billions in operating cash flow. That cash engine underpins ongoing share repurchases and a rising dividend—a reminder that Apple’s AI ambitions are funded by one of the most robust balance sheets in corporate history.

In market terms, Cupertino is rebranding—without saying so explicitly—from a “hardware story” to a full‑stack, cash‑compounding AI infrastructure play that happens to sit in the pockets, on the wrists, and on the desks of more than a billion users.

Services, Subscriptions, and the Art of Getting Paid More Than Once

While headlines focus on chips and training clusters, Apple’s services segment has been quietly upgrading the company’s margin profile and strategic leverage. Recent price increases for Apple Music and related bundles—nudging individual and family plans higher while citing rising licensing costs—illustrate Apple’s ability to exercise pricing power without destabilizing its ecosystem.

For investors, this matters for three reasons. First, services revenues carry structurally higher margins than hardware, strengthening earnings quality across cycles. Second, subscription price increases, justified by content and licensing inflation, demonstrate Apple’s capacity to pass through rising costs rather than absorb them. Third, every incremental subscription dollar flows through an ecosystem already deeply embedded in consumer routines, making churn more a risk to monitor than a base-case assumption.

In effect, Apple has built a business where it gets paid when you buy the device, paid again when you subscribe, and paid a third time when you stay—and the services flywheel turns AI from a buzzword into a monetizable, recurring feature set.

AAPL vs. NVDA: Different Spots on the Same AI Chessboard

Nvidia’s remarkable run has defined the “picks-and-shovels” phase of the AI trade, where model training, GPU capacity, and data-center arms races commanded premium valuations. Yet recent trading has tightened the gap between NVDA and AAPL, with single sessions now enough to flip the title of “world’s most valuable company.”

The emerging message from the tape is straightforward: the market is beginning to differentiate between “AI exposure” and “AI infrastructure plus monetization moat.” Nvidia sells the compute that powers AI models; Apple owns endpoints, subscriptions, and the behavioral rails where AI will actually be experienced—and paid for—by consumers and enterprises.

Apple, notably, has not tried to win the arms race on model branding. Instead, it has focused on infusing “intelligence” across operating systems, first‑party apps, and services, keeping the emphasis on experience rather than algorithm. For investors, that restraint looks increasingly like a feature, not a bug: less hype risk, more monetization clarity.

Intelligence as an Operating System, Not Just a Feature

Apple’s communications around upcoming software generations emphasize “innovative features and intelligence experiences” woven through iOS, macOS, watchOS, and services rather than marketed as standalone AI products. This framing is subtle but critical. AI is positioned as an embedded capability that makes devices more useful, services more engaging, and the ecosystem stickier.

Viewed through an institutional lens, this makes AAPL an AI infrastructure play with:

  • A global installed base as the distribution grid.
  • Services and subscriptions as the monetization engine.
  • A disciplined capital-return program as the shareholder-relations backbone.

For sophisticated retail investors, it presents an opportunity to gain AI exposure via a company that already knows how to convert technology cycles into cash dividends, buybacks, and long‑term compounding—rather than asking shareholders to underwrite a multi‑year path to profitability.

Why AAPL’s Setup Is Investor-Magnetic Right Now

For allocators and active investors looking for AI participation with downside awareness, the current Apple setup offers a rare blend of narrative, numbers, and optionality:

  • Leadership and signaling – Apple’s move back to the top of the market‑cap table underscores a rotation toward cash‑rich, execution‑focused platforms instead of pure thematic trades.
  • Earnings quality – A diversified revenue mix, high‑margin services, and robust free cash flow support ongoing capital returns alongside growth investments.
  • AI embedded, not advertised – Intelligence is being built into the operating system layer, turning AI from a stand-alone story into a structural upgrade to Apple’s existing profit engines.
  • Pricing power in practice – Subscription price adjustments, particularly in Apple Music and bundles, show that Apple can respond to cost pressures while preserving margins and relationships.

The Takeaway

The investment takeaway is clear: Apple may now represent the most balanced expression of the AI theme in public markets—participating across devices, services, and intelligence, while still behaving like a disciplined, shareholder‑focused compounder.

The Sources

Here’s a clean, numbered list of key sources you can reference or link from your Vista/Tribe content:

  1. Apple Investor Relations – Official filings, earnings, and capital-return updates
    https://investor.apple.com/investor-relations/default.aspx
  2. Apple reports second quarter 2026 results – Revenue, EPS, and cash-flow detail
    https://www.apple.com/newsroom/2026/04/apple-reports-second-quarter-results/
  3. Reuters – Apple unseats Nvidia to become the world’s most valuable company
    https://www.reuters.com/business/apple-closes-nvidia-race-worlds-most-valuable-company-2026-07-17/
  4. CNBC – Apple, Nvidia vie for title of world’s most valuable company
    https://www.cnbc.com/2026/07/17/apple-nvidia-aapl-nvda-market-cap.html
  5. Al Jazeera – Apple regains top spot as world’s most valuable company
    https://www.aljazeera.com/economy/2026/7/17/apple-regains-top-spot-as-worlds-most-valuable-company
  6. Eastern Herald – Apple overtakes Nvidia as world’s most valuable company
    https://easternherald.com/2026/07/18/apple-nvidia-most-valuable-company-market-cap/
  7. Financial Express – Apple unseats Nvidia from the top spot
    https://www.financialexpress.com/market/global-markets/apple-unseats-nvidia-from-the-top-spot-to-become-the-worlds-most-valuable
  8. Cryptopolitan – Apple passes Nvidia to become world’s most valuable company
    https://www.cryptopolitan.com/apple-passes-nvidia-most-valuable-company/
  9. Euronews – Apple surpasses Nvidia as world’s most valuable company
    https://www.euronews.com/business/2026/07/17/apple-briefly-surpasses-nvidia-as-worlds-most-valuable-company
  10. Motley Fool – Apple is about 4% away from overtaking Nvidia
    https://www.fool.com/investing/2026/07/03/apple-is-about-4-away-from-overtaking-nvidia-as-th
  11. Variety – Apple Music hikes subscription prices, citing rising licensing fees
    https://variety.com/2026/music/news/apple-music-raises-prices-licensing-fees-1236814878/
  12. The Apple Post – Apple increases Apple Music and Apple One subscription prices
    https://www.theapplepost.com/2026/07/17/70964/apple-increases-apple-music-and-apple-one-subscription-prices/
  13. MacRumors – Apple Music price increase details
    https://www.macrumors.com/2026/07/17/apple-music-price-increase/
  14. Forbes – Apple confirms Apple Music price rise and the reason why
    https://www.forbes.com/sites/davidphelan/2026/07/17/apple-confirms-apple-music-price-rise-and-the-reason-why/
  15. Macrotrends – Apple market cap historical data
    https://www.macrotrends.net/stocks/charts/AAPL/apple/market-cap
  16. CompaniesMarketCap – Apple (AAPL) market capitalization
    https://companiesmarketcap.com/apple/marketcap/
  17. Capital.com – Apple Inc (AAPL) Market Cap – July 2026 update
    https://capital.com/en-int/markets/shares/apple-inc-share-price/market-cap
  18. Trading Economics – Apple market capitalization
    https://tradingeconomics.com/aapl:us:market-capitalization
  19. StatMuse Money – Apple market cap 2026
    https://www.statmuse.com/money/ask/apple-market-cap-2026
  20. Public.com – Apple (AAPL) market cap today
    https://public.com/stocks/aapl/market-cap

July 17, 2026

AI Highs, Rate Jitters, and Lilly’s Psychedelic Shopping Spree: The Week Wall Street Needed a Therapist – July 17, 2026 -( $AMWL $HPP Rise!)

U.S. equities ended the week of July 17, 2026 on a cautious note, with major indexes consolidating recent gains as investors digested mixed earnings, firmer rate‑hike expectations, and evolving macro risks from weather, energy, and policy.

Equity markets: tech fatigue, earnings rotation

Wall Street traded choppy through the week, with the S&P 500 (^GSPC) off 1.55% at 7,457.69, Nasdaq Composite (^IXIC) off 2.90% at 25,520.24, and Dow Jones Industrial Average (^DJI) off .93% at 52,146.42 over the last 5-days & oscillating as second‑quarter earnings unexpectedly shifted leadership away from mega‑cap technology toward more cyclical and defensive sectors. The small caps on the Russell 200 held up relatively well and closed at 2,962.22, -.52% over the last 5-days. Technology and AI‑linked names that powered year‑to‑date performance saw profit‑taking as investors weighed premium valuations against an increasingly hawkish Federal Reserve backdrop. Financials, select industrials, and health‑care stocks showed relative resilience as investors rotated toward cash‑flow‑rich, dividend‑paying businesses better positioned for higher real yields and late‑cycle dynamics. Option market activity pointed to elevated short‑dated hedging around key earnings prints and macro releases, reinforcing a narrative of tactical rather than structural risk‑off behavior.

Macroeconomy: smoke, sentiment, and the Fed

Macro data and exogenous shocks shared the spotlight with earnings. A major smoke event was reported as threatening up to 180 million Americans, raising fresh near‑term concerns about health outcomes, productivity, and localized consumption patterns. This environmental overhang adds another layer of uncertainty for service‑sector foot traffic and labor supply in the affected regions. At the same time, consumer sentiment improved as lower gasoline prices offered incremental relief at the pump, supporting real disposable income and discretionary spending capacity heading into late summer. Those tailwinds are counterbalanced by a renewed chorus of voices arguing the Federal Reserve should resume or extend rate hikes to ensure inflation expectations remain anchored, particularly as shelter and services inflation prove sticky. With mortgage rates drifting higher—Freddie Mac’s 30‑year fixed rate averaging in the mid‑6% range for the week—housing affordability remains strained, fattening the policy trade‑off between inflation control and growth risks. Consumer prices unexpectedly fell 0.4% in June while producer prices dropped 0.3%, delivering a twin downside surprise on inflation that strengthened the case for a more patient Fed even as year‑over‑year pressures remain above target. For institutional allocators, the macro mix—environmental disruptions, marginally better sentiment, and a still‑hawkish Fed reaction function—supports a barbell approach: quality growth with pricing power on one end, and defensive, cash‑generative equities on the other.

Policy and market structure: event markets under scrutiny

Policy risk moved beyond traditional monetary and fiscal domains into the plumbing of markets themselves. A Trump‑era regulator reportedly ordered prediction‑market platform Kalshi to defy constraints around certain political event contracts, keeping the spotlight on how derivative‑like instruments intersect with election cycles and regulatory oversight. The dispute underscores a broader tension: retail demand for event‑driven trading vehicles is rising, yet regulators remain wary of products that blur the boundary between capital markets, gambling, and democratic processes. For traders and market‑structure specialists, the Kalshi narrative is a reminder to monitor how CFTC and SEC interpretations could reshape liquidity in event futures, options tied to binary political outcomes, and retail‑facing structured products. Positioning around U.S. election risk may need to lean more heavily on listed index options, volatility products, and sector rotation instead of niche event contracts as regulatory scrutiny intensifies.

Health‑care and biotech: strategic M&A and leadership shifts

Health‑care and biotech were a relative bright spot, with deal‑flow and corporate leadership changes reinforcing the sector’s strategic importance in a higher‑rate environment. Eli Lilly (LLY) advanced its pipeline strategy by agreeing to acquire assets from Atai Life Sciences (ATAI) and Beckley Psytech (privately held), aiming to accelerate next‑generation neuropsychiatric and central‑nervous‑system therapies. The transaction highlights two key themes: large‑cap pharma’s willingness to pay for de‑risked innovation, and the ongoing consolidation of smaller platform biotechs into scaled global franchises.

Separately, CVS Health (CVS) remained in focus following commentary around CEO‑level leadership and strategic priorities, emphasizing integrated care delivery, pharmacy benefit management, and cost‑containment initiatives across its footprint. In a macro backdrop where real rates pressure long‑duration growth stories, health‑care’s combination of secular demand, M&A optionality, and cash‑flow support continues to attract both defensive and growth‑oriented capital,

For biotech‑oriented investors, the Lilly–Atai tie‑up reinforces the importance of owning platforms with differentiated mechanisms of action and clear paths to partnering or takeout, particularly in CNS, obesity, and immunology.

Positioning Takeaway

The week ending July 17, 2026 reinforces three investable narratives: first, the AI and semiconductor complex remains structurally attractive, but the market is increasingly discriminating on valuation and earnings quality; second, macro volatility from environmental shocks, rates, and policy favors quality factor tilts and robust risk‑management overlays; and third, health‑care and biotech continue to offer idiosyncratic alpha through M&A, differentiated pipelines, and leadership transitions. A practical illustration: a portfolio balancing core exposure to diversified U.S. benchmarks like the SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) with satellite positions in select large‑cap pharma (e.g., Eli Lilly (LLY)) and defensive health‑care services (e.g., CVS Health (CVS)) may capture ongoing earnings and innovation upside while cushioning against policy and macro shocks discussed this week

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $13.23, +33.50% over the last 5-days.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $15.72, +3.56% over the last 5-days) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.59) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.98), a leader in innovative, patient-centric insulin delivery, released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $6.96, +4.50% over the past 5-days), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $202.81.

The InterGroup Corporation (INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $39.08.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.29) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.57), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $21.52 is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

The Sources

  1. CNBC – “Stock market today: Live updates” (July 16, 2026)
  2. Yahoo Finance – “Stock market today: Friday, July 17 – Dow, S&P 500, Nasdaq live updates”
  3. Yahoo Finance – “180 million Americans threatened by smoke”
  4. Yahoo Finance – “Consumer sentiment climbs as lower gas prices offer some relief”
  5. Yahoo Finance – “Fed rate‑hike voices swell”
  6. Yahoo Finance – “Trump regulator orders Kalshi to defy…” (options / market‑structure piece)
  7. Yahoo Finance – “Lilly to acquire Atai/Beckley to advance therapies”
  8. Yahoo Finance – “CVS Health CEO David Joyner…”

Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved